产品描述信息
NR-14893??Mycobacterium tuberculosis, CDC1551, Transposon Mutant 182 (MT0510, Rv0491)(Mutant Bacteria)|Mycobacterium tuberculosis|CDC1551, Transposon Mutant 182 (MT0510, Rv0491)||NIH - TB Vaccine Testing and Research Materials ContractAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Mycobacterium tuberculosis, Strain CDC1551, Transposon Mutant 182 (MT0510, Rv0491), NR-14893."|
Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
At this time, BEI Resources only maintains seed stock of this item. Once a request is received for this item, it will be added to our production queue. Please allow ample time for distribution lots to be made available.
In 2002, TARGET (Tuberculosis Animal Research and Gene Evaluation Taskforce) was formed to enable the modeling of human tuberculosis in multiple animal species using defined protocols and testing defined mutants of M. tuberculosis. In addition to animal modeling activities, a library of intragenic transposon mutants has been created and characterized. M. tuberculosis, transposon mutant 182 was created by disruption of a DNA-binding response regulator (MT0510, Rv0491), of the wild-type strain CDC1551.
Each tube contains a Lowenstein-Jensen (LJ) agar slant that was inoculated with 0.1 mL of bacterial culture and incubated 2 to 4 weeks at 37°C. TARGET: Rv0491MT Number (JCVI): MT0510TubercuList: Rv0491Orf Description: DNA-binding response regulator Orf Size: 693POI: 199
Additional information is available at Mycobacterium tuberculosis CDC1551 Transposon Mutant Library.
This mutant was developed by Lamichhane, et al. at the Center for Tuberculosis Research, The Johns Hopkins University School of Medicine, PubMed:
12775759.